Sam Schulman.

In the warfarin group, the INR was in the therapeutic range for a median of 65.3 percent of the time. The INR was below the therapeutic range 17.3 percent of that time period and above the therapeutic range 12.2 percent of that time period. Additional features of the remedies are provided in Table 1. In the active-control research, the study drug was halted early in 276 patients in the dabigatran group and in 281 sufferers in the warfarin group . In the placebo-control study, 3 individuals assigned to placebo received dabigatran through the entire study mistakenly., a leading RNAi therapeutics company, announced today that it has initiated a Stage IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus infection. RSV illness in lung transplant individuals represents an important unmet medical want; the problem is associated with significant morbidity, including the development of severe lung transplant rejection in 10 percent to 20 percent of infected patients. Lung transplant patients contaminated with RSV are in risk for a rise in frequency also of fresh or progressive bronchiolitis obliterans syndrome , a life-threatening complication representing an irreversible disease of the transplanted lung leading to approximately 50 percent mortality within 3 to 5 years of onset.D., Ph.D., Senior Vice President, Clinical Analysis at Alnylam.